Statement from No Patient Left Behind on the Finalized CMS GLOBE Model
WASHINGTON, DC - October 1, 2026 - No Patient Left Behind Executive Director Priscilla VanderVeer issued the following statement on the Centers for Medicare & Medicaid Services' finalized Global Benchmark for Efficient Drug Pricing (GLOBE) Model:
“GLOBE's core flaw is that it imports prices from wealthy countries that underpay for innovation and limit access to new medicines. Instead of copying countries that use 'value' measures that discriminate against their most vulnerable patients, the U.S. should use trade tools to make those countries pay their fair share.
“We’re glad CMS listened to stakeholders on some points, like excluding orphan-only drugs, plasma-derived products, and certain cell and gene therapies. We’re also glad to see it will lower what patients in traditional Medicare pay for medicines, especially since there is no out-of-pocket cap in Part B.
“But the model still leaves American patients and taxpayers subsidizing foreign health systems, and forces a false choice between affording the medicines available today and funding future breakthroughs. And it doesn’t address how the private and public insurance system makes people pay twice for the care they need, through a monthly premium and then high out-of-pocket costs when they seek treatment. Policymakers can lower patient costs, protect the incentives that drive breakthroughs, and demand that other nations do their part to support future cures. We’re committed to helping them do so.”
About No Patient Left Behind
No Patient Left Behind (NPLB) is a coalition of biotechnology innovators, investors, healthcare professionals, economists, and patient advocates working to ensure that patients have access to the medicines they need today and in the future. Learn more about NPLB’s latest initiatives at www.nopatientleftbehind.org.